What is claimed is:

1. A compound of formula I or a pharmaceutically acceptable salt thereof:

$$\begin{array}{c|c}
R^{F1} & Z \\
N & R^{F2}
\end{array}$$

$$\begin{array}{c|c}
R^{1} & R^{2} \\
R^{1} & R^{2}
\end{array}$$

Ī

5

10

15

20

25

30

wherein R^{F1} and R^{F2} are independently C_{1-6} alkyl substituted by one or more groups selected from -F, -Cl, -Br, -NO₂, -CN, -OH, -CHO, -C(=O)-R' and -OR', wherein R' is a C_{1-3} alkyl;

Z is selected from O= and S=;

R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R³R⁴N-C₁₋₆alkyl, R³O-C₁₋₆ alkyl, R³C(=O)N(-R⁴)-C₁₋₆alkyl, R³R⁴NS(=O)₂-C₁₋₆alkyl, R³CS(=O)₂N(-R⁴)-C₁₋₆alkyl, R³R⁴NS(=O)₂N(R⁵)-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁-6alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, R³R⁴N-, R³O-, R³C(=O)N(-R⁴)-, R³R⁴NS(=O)₂-, R³CS(=O)₂N(-R⁴)-, R³R⁴NC(=O)N(-R⁵)-, R³R⁴NS(=O)₂N(R⁵)-, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and R³R⁴N-;

R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R³R⁴N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and R³R⁴N-; and

 R^3 and R^4 and are independently selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and a divalent C_{1-6} group that together with another divalent C_{1-6} group selected from R^3 and R^4 forms a portion of a ring.

2. A compound as claimed in claim 1, wherein

R^{F1} and R^{F2} are independently selected from -CF₃, -CH₂CF₃, -CH₂CHF₂, -CHFCF₃, -CHFCF₃, -CHFCH₂, -CHFCH₂F, -CF₂CH₃, -CF₂CH₂F, -CF₂CHF₂, -CF₃, -CH₂CCl₃, -CH₂CHCl₂, -CH₂CBr₃, -CH₂CHBr₂, -CH₂NO₂, -CH₂CH₂NO₂, -CH₂CN, -CH₂CH₂CN, and -CH₂CH₂OCH₃;

10 Z is O=;

5

15

20

25

30

 R^1 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, R^3R^4N - C_{1-4} alkyl, R^3O - C_{1-4} alkyl, $R^3C(=O)N(-R^4)$ - C_{1-4} alkyl, phenyl- C_{1-4} alkyl, phenyl-C(=O)- C_{1-4} alkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, C_{3-6} heterocyclyl-C(=O)- C_{1-4} alkyl, R^3R^4N -, R^3O -, $R^3R^4NS(=O)_2$ -, C_{6-10} aryl, C_{6-10} aryl-C(=O)-, C_{3-10} cycloalkyl, C_{4-6} cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl-C(=O)-; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl- C_{1-4} alkyl, phenyl-C(=O)- C_{1-4} alkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocyclyl-C(=O)- C_{1-4} alkyl, C_{6-10} aryl-C(=O)-, C_{3-10} cycloalkyl, C_{4-6} cycloalkenyl, C_{3-6} heterocyclyl-C(=O)- C_{1-4} alkyl, C_{3-6} heterocyclyl-C(=O)-, C_{3-10} cycloalkyl, C_{4-6} cycloalkenyl, C_{3-6} heterocyclyl or C_{3-10} cycloalkyl, C_{4-6} cycloalkenyl, $C_$

R² is selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl, C₃₋₅heteroaryl, R³R⁴N-, phenyl and C₃₋₆heterocycloalkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl, C₃₋₅heteroaryl, phenyl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and R³R⁴N-; and R³ and R⁴ are independently selected from -H, C₁₋₆alkyl and C₂₋₆alkenyl.

3. A compound as claimed claim 1, wherein

R^{F1} and R^{F2} are independently selected from -CF₃, -CH₂CF₃, -CH₂CHF₂, -CHFCF₃, -CHFCH₂F, -CF₂CF₃, -CF₂CH₃, -CF₂CH₂F, -CF₂CHF₂, and -CF₃;

Z is O=;

10

15

20

25

30

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, R³R⁴N-, R³R⁴N-C₁₋₄alkyl, R³O-C₁₋₄alkyl, R³C(=O)N(-R⁴)-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, phenyl-C(=O)-C₁₋₄alkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₆alkyl, C₂₋₆alkenyl, R³R⁴N-C₁₋₄alkyl, R³O-C₁₋₄alkyl, R³C(=O)N(-R⁴)-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and R³R⁴N-:

 R^2 is selected from the group consisting of C_{1-6} alkyl, C_{3-10} cycloalkyl, R^3R^4N -, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl, C_{3-5} heteroaryl, and phenyl wherein said C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl, C_{3-5} heteroaryl, and phenyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and R^3R^4N -; and

R³ and R⁴ are independently selected from -H, C₁₋₆alkyl and C₂₋₆alkenyl.

A compound as claimed in claim 1, wherein R^{F1} and R^{F2} are -CH₂CF₃;
 Z is O=;

R¹ is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl, propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl, methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl, cyclohexyloxy, cyclohexylamino, dimethylaminoethyl, 4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl, 1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl, N-methyl-2-piperidylmethyl, 3-thienylmethyl, (2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl, (5-(acetoxymethyl)-2-furyl)methyl), (2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl); and

R² is selected from t-butyl, n-butyl, 2-methyl-2-butyl, cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl, 1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl, tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl, and N-morpholinyl.

25

- 5. A compound selected from 2-tert-Butyl-1-(cyclohexylmethyl)-N,N-bis(2,2,2-trifluoroethyl)-1H-benzimidazole-5-carboxamide and pharmaceutically acceptable salts thereof.
- 5 6. A compound according to any one of claims 1-5 for use as a medicament.
 - 7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain.
- 10 8. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of anxiety disorders.
 - 9. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiavascular disorders..
 - 10. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.
- 20 11. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.
 - 12. A method for preparing a compound of formula I,

$$\begin{array}{c|c}
R^{F1} & \nearrow & \nearrow & R^2 \\
R^{F2} & \nearrow & R^1
\end{array}$$

Ī

comprising the step of reacting a compound of formula II,

25

П

with a compound of R²C(=O)-X to form the compound of formula I, wherein

R^{F1} and R^{F2} are independently selected from -CF₃, -CH₂CF₃, -CH₂CHF₂, -CHFCF₃, -CHFCH₂, -CF₂CF₃, -CF₂CH₃, -CF₂CH₂F, -CF₂CHF₂, and -CF₃;

Z is selected from O= and S=;

X is selected from -Cl, -Br, -I, -OH, -OCH3, and -OCH2CH3;

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, R³R⁴N-C₁₋₄alkyl, R³O-C₁₋₄alkyl,

R³C(=O)N(-R⁴)-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, phenyl-C(=O)-C₁₋₄alkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₆alkyl, C₂₋₆alkenyl, R³R⁴N-C₁₋₄alkyl, R³O-C₁₋₄alkyl, R³C(=O)N(-R⁴)-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl-C(=O)-used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and R³R⁴N-;

R² is selected from the group consisting of C₁₋₆alkyl, C₃₋₆cycloalkyl, R³R⁴N-,

C₃₋₆cycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₅heteroaryl, and phenyl wherein said C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl,

C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₅heteroaryl, and phenyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and

R³ and R⁴ are independently selected from -H, C₁₋₆alkyl and C₂₋₆alkenyl.